Literature DB >> 26099008

Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Robertson Mackenzie1, Aline Talhouk, Sima Eshragh, Sherman Lau, Daphne Cheung, Christine Chow, Nhu Le, Linda S Cook, Nafisa Wilkinson, Jacqueline McDermott, Naveena Singh, Friedrich Kommoss, Jacobus Pfisterer, David G Huntsman, Martin Köbel, Stefan Kommoss, C Blake Gilks, Michael S Anglesio.   

Abstract

Epithelial ovarian cancer (EOC) consists of 5 major histotypes: high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), mucinous carcinoma (MC), and low-grade serous carcinoma (LGSC). Each can have a broad spectrum of morphologic appearances, and 1 histotype can closely mimic histopathologic features more typical of another. Historically, there has been a relatively high frequency of mixed, defined by 2 or more distinct histotypes present on the basis of routine histopathologic assessment, histotype carcinoma diagnoses (3% to 11%); however, recent immunohistochemical (IHC) studies identifying histotype-specific markers and allowing more refined histotype diagnoses suggest a much lower incidence. We reviewed hematoxylin and eosin-stained slides from 871 cases of EOC and found the frequency of mixed carcinomas to be 1.7% when modern diagnostic criteria are applied. Through international collaboration, we established a cohort totaling 22 mixed EOCs, consisting of 9 EC/CCC, 4 EC/LGSC, 3 HGSC/CCC, 2 CCC/MC, and 4 other combinations. We interrogated the molecular differences between the different components of each case using IHC, gene expression, and hotspot sequencing analyses. IHC data alone suggested that 9 of the 22 cases were not mixed tumors, as they presented a uniform immuno-phenotype throughout, and these cases most probably represent morphologic mimicry and variation within tumors of a single histotype. Synthesis of molecular data further reduces the incidence of mixed carcinomas. On the basis of these results, true mixed carcinomas with both morphologic and molecular support for the presence of >1 histotype within a given tumor represent <1% of EOCs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26099008      PMCID: PMC4604016          DOI: 10.1097/PAS.0000000000000476

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  45 in total

1.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.

Authors:  Akira Tsuchiya; Michiie Sakamoto; Jun Yasuda; Makoto Chuma; Tsutomu Ohta; Misao Ohki; Toshiharu Yasugi; Yuji Taketani; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

3.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

4.  Molecular genetic evidence that endometriosis is a precursor of ovarian cancer.

Authors:  Amanda H Prowse; Sanjiv Manek; Rajesh Varma; Jinsong Liu; Andrew K Godwin; Eamonn R Maher; Ian P M Tomlinson; Stephen H Kennedy
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

5.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

6.  Calculator for ovarian carcinoma subtype prediction.

Authors:  Steve E Kalloger; Martin Köbel; Samuel Leung; Erika Mehl; Dongxia Gao; Krista M Marcon; Christine Chow; Blaise A Clarke; David G Huntsman; C Blake Gilks
Journal:  Mod Pathol       Date:  2010-12-03       Impact factor: 7.842

7.  Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci.

Authors:  X Jiang; A Hitchcock; E J Bryan; R H Watson; P Englefield; E J Thomas; I G Campbell
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

8.  Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.

Authors:  Robert C Young; Mark F Brady; Roberta K Nieberg; Harry J Long; Allan R Mayer; Samuel S Lentz; Jean Hurteau; David S Alberts
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

Review 9.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.

Authors:  Jie Li; Oluwole Fadare; Li Xiang; Beihua Kong; Wenxin Zheng
Journal:  J Hematol Oncol       Date:  2012-03-09       Impact factor: 17.388

10.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Authors:  Joshua Z Press; Alessandro De Luca; Niki Boyd; Sean Young; Armelle Troussard; Yolanda Ridge; Pardeep Kaurah; Steve E Kalloger; Katherine A Blood; Margaret Smith; Paul T Spellman; Yuker Wang; Dianne M Miller; Doug Horsman; Malek Faham; C Blake Gilks; Joe Gray; David G Huntsman
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

View more
  19 in total

Review 1.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

Review 2.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

3.  Histotype classification of ovarian carcinoma: A comparison of approaches.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Michael Anglesio; Kristine Wicklund; Rex Bentley; Andrew Berchuck; Linda E Kelemen; Tayyebeh M Nazeran; C Blake Gilks; Holly R Harris; David G Huntsman; Joellen M Schildkraut; Mary Anne Rossing; Martin Köbel; Jennifer A Doherty
Journal:  Gynecol Oncol       Date:  2018-08-16       Impact factor: 5.482

Review 4.  [Current WHO classification of the female genitals : Many new things, but also some old].

Authors:  Doris Mayr; Elisa Schmoeckel; Anne Kathrin Höhn; Grit Gesine Ruth Hiller; Lars-Christian Horn
Journal:  Pathologe       Date:  2021-04-06       Impact factor: 1.011

5.  MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Authors:  Eun Young Kang; Joshua Millstein; Gordana Popovic; Nicola S Meagher; Adelyn Bolithon; Aline Talhouk; Derek S Chiu; Michael S Anglesio; Betty Leung; Katrina Tang; Neil Lambie; Marina Pavanello; Annalyn Da-Anoy; Diether Lambrechts; Liselore Loverix; Siel Olbrecht; Christiani Bisinotto; Jesus Garcia-Donas; Sergio Ruiz-Llorente; Monica Yagüe-Fernandez; Robert P Edwards; Esther Elishaev; Alexander Olawaiye; Sarah Taylor; Beyhan Ataseven; Andreas du Bois; Philipp Harter; Jenny Lester; Claus K Høgdall; Sebastian M Armasu; Yajue Huang; Robert A Vierkant; Chen Wang; Stacey J Winham; Sabine Heublein; Felix K F Kommoss; Daniel W Cramer; Naoko Sasamoto; Lilian van-Wagensveld; Maria Lycke; Constantina Mateoiu; Janine Joseph; Malcolm C Pike; Kunle Odunsi; Chiu-Chen Tseng; Celeste L Pearce; Sanela Bilic; Thomas P Conrads; Arndt Hartmann; Alexander Hein; Michael E Jones; Yee Leung; Matthias W Beckmann; Matthias Ruebner; Minouk J Schoemaker; Kathryn L Terry; Mona A El-Bahrawy; Penny Coulson; John L Etter; Katherine LaVigne-Mager; Juergen Andress; Marcel Grube; Anna Fischer; Nina Neudeck; Greg Robertson; Rhonda Farrell; Ellen Barlow; Carmel Quinn; Anusha Hettiaratchi; Yovanni Casablanca; Ramona Erber; Colin J R Stewart; Adeline Tan; Yu Yu; Jessica Boros; Alison H Brand; Paul R Harnett; Catherine J Kennedy; Nikilyn Nevins; Terry Morgan; Peter A Fasching; Ignace Vergote; Anthony J Swerdlow; Francisco J Candido Dos Reis; G Larry Maxwell; Susan L Neuhausen; Arantzazu Barquin-Garcia; Francesmary Modugno; Kirsten B Moysich; Philip J Crowe; Akira Hirasawa; Florian Heitz; Beth Y Karlan; Ellen L Goode; Peter Sinn; Hugo M Horlings; Estrid Høgdall; Karin Sundfeldt; Stefan Kommoss; Annette Staebler; Anna H Wu; Paul A Cohen; Anna DeFazio; Cheng-Han Lee; Helen Steed; Nhu D Le; Simon A Gayther; Kate Lawrenson; Paul D P Pharoah; Gottfried Konecny; Linda S Cook; Susan J Ramus; Linda E Kelemen; Martin Köbel
Journal:  Virchows Arch       Date:  2021-11-15       Impact factor: 4.535

6.  Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Authors:  Martin Köbel; Li Luo; Xin Grevers; Sandra Lee; Angela Brooks-Wilson; C Blake Gilks; Nhu D Le; Linda S Cook
Journal:  Int J Gynecol Pathol       Date:  2019-07       Impact factor: 2.762

7.  Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β-catenin signaling.

Authors:  Shan Zhao; Yumei Ma; Xianghua Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27

9.  Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.

Authors:  Stefan Kommoss; C Blake Gilks; Andreas du Bois; Friedrich Kommoss
Journal:  Br J Cancer       Date:  2016-09-15       Impact factor: 7.640

10.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.

Authors:  Martin Köbel; Kurosh Rahimi; Peter F Rambau; Christopher Naugler; Cécile Le Page; Liliane Meunier; Manon de Ladurantaye; Sandra Lee; Samuel Leung; Ellen L Goode; Susan J Ramus; Joseph W Carlson; Xiaodong Li; Carol A Ewanowich; Linda E Kelemen; Barbara Vanderhyden; Diane Provencher; David Huntsman; Cheng-Han Lee; C Blake Gilks; Anne-Marie Mes Masson
Journal:  Int J Gynecol Pathol       Date:  2016-09       Impact factor: 2.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.